Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for treatment for gastric cancer. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark.
तुलना करने के लिए मीट्रिक्स | SCOLG | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधSCOLGपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −0.1x | −1.3x | −0.5x | |
PEG अनुपात | 0.00 | −0.09 | 0.00 | |
क़ीमत/बुक | 0.3x | 1.7x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 20.5x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 371.4% | 50.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 12.2% | 8.7% | अनलॉक करें |